1. Understanding the Mechanism of Radionuclides and Survival in Bone Mets in CRPC

2. The Challenge of Bone-Metastatic PC

3. PC: Unique Pattern of Metastasis

4. Biology of Bone Mets in PC

5. Tumor Cells Compete With Stem Cells in PC

6. "Vicious Cycle" of PC Bone Mets

7. Bone Mets in PC: Predisposing Factors

8. Consequences of Bony Metastatic Disease

9. FDA-Approved Bone-Targeted Treatments

10. "The Land of No Indication"

11. Approved Uses of Bone-Targeted Therapies

12. Dosing Zoledronic Acid and Denosumab in PC

13. Do Zoledronic Acid and Denosumab Add Value in the Modern Treatment Era?

14. Docetaxel  ZA: SRE-Free Interval

15. Enzalutamide Post-Docetaxel: Time to SRE

16. Enzalutamide Increases Fracture Rates

17. Abiraterone  Prednisone Postdocetaxel: Fractures (COU-AA-301)

18. Advanced PC: Heterogeneous Group of Diseases

19. Preferential Uptake of Radium-223 in Osteoblastic Lesions

20. ALSYMPCA Trial of Radium-223: Survival

21. ALSYMPCA Trial of Radium-223: Time to SSEs

22. ALSYMPCA Trial: Effects of Radium-223 on SSEs, Stratified by Bisphosphonate Use

23. Lessons From ALSYMPCA

24. Can Radium Add Value to Abiraterone or Enzalutamide in Bone-Metastatic CRPC?

25. If Concomitant Hormonal Therapy Is Used, When Should Radium-223 Be Added?

26. Potential to Target PSMA

27. PSA Decline With PSMA-Targeted Therapy

28. Case Report: PSMA-Targeted Alpha Emitter (Actinium-225)

29. The Future of Targeted Radiation in PC

30. Summary

31. Abbreviations